Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.
about
Antibiotic treatment for the sexual partners of women with bacterial vaginosisNew concepts of resistance in the treatment of Helicobacter pylori infectionsDetermining population and developmental pharmacokinetics of metronidazole using plasma and dried blood spot samples from premature infantsTreatment of Helicobacter pylori infection: Current and future insightsNitroimidazoles for the treatment of TB: past, present and futureMetronidazole-induced encephalopathy: not always a reversible situation.Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies.Microbiologic response to treatment of bacterial vaginosis with topical clindamycin or metronidazole.Clinical pilot study: efficacy of triple antibiotic therapy in Blastocystis positive irritable bowel syndrome patientsTinidazole for bacterial vaginosis.Metronidazole decreases viability of DLD-1 colorectal cancer cell line.Optimization, characterisation and pharmacokinetic studies of mucoadhesive oral multiple unit systems of ornidazole.Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infantsProspective observational study comparing three different treatment regimes in patients with Clostridium difficile infection.Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques.Atypical metronidazole-induced encephalopathy in anaerobic brain abscess.Tinidazole for the treatment of vaginal infections.Metronidazole single versus multiple daily dosing in serious intraabdominal/pelvic and diabetic foot infections.Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosisNitroimidazole carboxamides as antiparasitic agents targeting Giardia lamblia, Entamoeba histolytica and Trichomonas vaginalis.Guidelines for the treatment of bacterial vaginosis: focus on tinidazoleThe role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalystMetronidazole and hydroxymetronidazole central nervous system distribution: 1. microdialysis assessment of brain extracellular fluid concentrations in patients with acute brain injury.Metronidazole-induced encephalopathy in a patient with Crohn's diseasePolyethylene glycol-based hydrogels for controlled release of the antimicrobial subtilosin for prophylaxis of bacterial vaginosis.Persistent and recurrent Trichomonas vaginalis infections: epidemiology, treatment and management considerations.Safety of antimicrobial treatment during pregnancy: a current review of resistance, immunomodulation and teratogenicity.Dosing antibiotics in neonates: review of the pharmacokinetic data.An Update on Medical Treatment Options for Hidradenitis Suppurativa.Antibiotic treatment for the sexual partners of women with bacterial vaginosis.Substrate specificity of the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles.Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica.Pathogenic Nocardia, Rhodococcus, and related organisms are highly susceptible to imidazole antifungalsDisposition and Residue Depletion of Metronidazole in Pigs and Broilers.Systemic antibiotic prophylaxis prior to gastrointestinal surgery - is oral administration of doxycycline and metronidazole adequate?Efficacy of Natural and Allopathic Antimicrobial Agents Incorporated onto Guided Tissue Regeneration Membrane Against Periodontal Pathogens: An in vitro Study.Sequential Therapy for Helicobacter Pylori Eradication: The Time is Now!Mode of action and bactericidal properties of surotomycin against growing and nongrowing Clostridium difficile.The Natural Antimicrobial Subtilosin A Synergizes with Lauramide Arginine Ethyl Ester (LAE), ε-Poly-L-lysine (Polylysine), Clindamycin Phosphate and Metronidazole, Against the Vaginal Pathogen Gardnerella vaginalis.Metronidazole plus rifampin sterilizes long-term dormant Mycobacterium tuberculosis.
P2860
Q24188259-EB5E61CA-223C-4946-847E-AE77F0251BA7Q24622513-457039F1-51F7-4E64-A054-553F038DFA43Q24626231-8EAC09AF-AADF-488C-8195-619F11BE7698Q26769707-F47E0916-F0CD-493D-9547-FC683B664A0EQ26849554-466F63B5-CF7F-4F2C-BF16-85BD16ABB725Q33419619-60A6F51E-C7BD-4506-A113-6885773C404FQ33681753-365330B4-CDBE-4C46-8DC1-65284F6F4F16Q34042211-42A5D080-7D0D-4E2A-BF53-83D67BB98B9BQ34404910-C0B31A6A-39D0-43E0-8800-5829923C5685Q34580014-A4E1ACBB-A1CC-4F80-B6D0-F3ABE450CB9BQ34777135-E3A72E01-E2FB-44E6-8C37-534D127D4544Q34991067-31E351F6-1534-4B54-8532-09CE78F783A6Q35867330-9FEBFC77-D027-4FAF-B9F8-6E56207AF4CFQ35867366-2771C271-F2FD-4777-B114-5B0B61CD5252Q36212962-8FFF5E1C-4BDC-491D-A337-01D7AD290E55Q36354133-CF1C7AAF-11F4-4356-B20C-8EBE4932BE8AQ36802639-E4A47F0C-D97B-4282-B02A-79B7F8DC1A2CQ36940327-7082967D-6195-4592-B0CB-14C1D3C2B1DDQ37036566-7E2F0B3B-C859-4CB0-9289-EA70252F1E60Q37037261-D4F409DF-4FE1-4A64-BE5C-A50459089955Q37261052-49E188D6-33C4-4393-A1C7-09B442726833Q37422732-CEE24189-2B17-4EB3-93D7-8C06FAAA914FQ37544593-A64A4BD9-696C-4454-B62E-4717FB1CE952Q37662488-EF99EDC8-7592-4CB3-9D9B-CDA8EF17C521Q37713013-9F998016-A4E1-4E7E-923D-6ECF47B36C17Q38189822-B27343E1-0A28-4BFB-B9A0-851DEC3165D0Q38246106-5EE00383-9F2D-4904-8BCF-DBD8A7ACEB39Q38649419-306F3FE6-4365-4F06-99FC-CBE1638A4A81Q38667207-92EF5D80-4496-4D7B-9C39-9F4A0C5E0120Q38970652-AFCF26BC-4516-443E-BF51-81E145651920Q39037669-3F076977-C35F-40CB-A321-B201F6D91DD4Q39444318-70646966-B080-40BB-9FAF-54E85621F907Q39743340-08A7655B-A34C-4F46-9784-914E6FCB510FQ40107310-86D1EA46-A755-4230-B575-9D5D07D01E7CQ40155259-4DA49435-0409-4A07-AE84-98D83A56F17DQ40302913-34DEED97-4341-4EEB-A3EE-E023661D791AQ41173895-E7C5B508-EBE2-4683-9996-3B9864AD7979Q41175414-BFB75BC1-5873-400F-BF5D-671446616A11Q41544969-FFE2A776-82FF-4A4E-8B1A-CFB3F3D0C49FQ41853471-D78102F3-F73F-4BF5-A051-AC5654192D8A
P2860
Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.
@ast
Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.
@en
type
label
Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.
@ast
Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.
@en
prefLabel
Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.
@ast
Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.
@en
P2093
P1476
Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.
@en
P2093
P304
P356
10.2165/00003088-199936050-00004
P577
1999-05-01T00:00:00Z
P6179
1048534840